While B-cell malignancies dominate Zanubrutinib's applications, emerging research suggests breakthrough potential in autoimmune disease management and transplant medicine. The drug’s ability to modulate immune responses is being explored for treating rheumatoid arthritis, multiple sclerosis, and graft-versus-host disease (GVHD).
Key Areas of Exploration:
Autoimmune Disease – Controlling overactive B-cell responses in lupus & RA
Transplant Medicine – Preventing organ rejection by balancing immune activation
Personalized Therapy – Genetic profiling to optimize BTK inhibitor effectiveness
Market Leaders Driving Innovation
| Company | Research Focus |
|---|---|
| Pfizer | Investigating Zanubrutinib for GVHD prevention |
| GlaxoSmithKline | Clinical trials on BTK inhibitors for autoimmune conditions |
| Sanofi | Exploring use cases in multiple immune-related disorders |
Check the full market forecast: DataString Consulting Report
Comments
0 comment